Estimated additional lifetime risk of cancer attributable to diagnostic CT in a pediatric bone marrow transplant cohort: Experience at a single academic institution

Jonathan O. Swanson¹*, Adam Alessio², Teresa Chapman¹

¹Department of Radiology, Seattle Children’s Hospital/University of Washington, Seattle, USA
²Department of Radiology, University of Washington, Seattle, USA
Email: jonathan.swanson@seattlechildrens.org

Received 5 December 2011; revised 21 December 2011; accepted 2 February 2012

ABSTRACT

Purpose: To determine the frequency of CT procedures in a cohort of bone marrow transplant patients and estimate the effective dose from each CT procedure as well as rough estimates of lifetime attributable risk (LAR) of cancer (both incidence and mortality). Background: Pediatric patients who undergo bone marrow transplant benefit greatly from the diagnostic power of computed tomography, but due to the need for frequent imaging, these patients are repeatedly exposed to the carcinogenic potential of ionizing radiation. Methods: CT Imaging and patient parameters were collected from a retrospective cohort of bone marrow transplant patients. Dosimetry was estimated as a function of age, dose length product (DLP), and scan region based on published DLP to effective dose tables. Lifetime attributable risk (LAR) of cancer as a function of age, gender, and organ specific dose was derived from BEIR VII phase 2 estimates. Results: 44 patients with bone marrow transplant were included and ranged in age from 7 months to 20 years (average age, 9 years). The average number of CT studies per patient was 3.2 over the 15 month period. The average effective dose for each study was 5.9 +/- 4.5 mSv. Cumulative effective dose to each patient was 20 +/- 32 mSv. It was estimated that in this cohort, the CT imaging performed over a 15-month period on a 64-slice scanner led to a lifetime additional risk of cancer incidence of 5 in 1000 and a lifetime additional risk of cancer mortality of 2 in 1000. Conclusion: Diagnostic CT is important in the assessment and management of ill patients following bone marrow transplant. The risk of ionizing radiation leading to additional development of cancer merits using as low a CT technique as reasonable to achieve a diagnostic study.

Keywords: Ionizing Radiation; Effective Dose; CT; Lifetime Additional Risk

1. INTRODUCTION

The evolution of computed tomography technology in the last 20 years has markedly improved our ability to image children. CT innovations have decreased scanning duration and improved spatial and temporal resolution [1]. These innovations, in turn, have reduced the need for sedation and have allowed the imaging of younger, sicker and less cooperative children [1,2]. Benefits of CT imaging, including avoidance of unnecessary exploratory laparotomies, the ability to diagnose disease earlier in its course, and the tracking of disease progression, have helped drive the rapid increase of CT use in children.

The commonly acknowledged primary risk of computed tomography is the increased potential for subsequent development of cancer [3-8]. Exposure to low-dose ionizing radiation has been shown to increase the incidence of cancer in the life long-studied cohort of Hiroshima and Nagasaki atomic bomb survivors, as well as in both occupational exposure studies and in medical radiation therapy studies. The pediatric population is at a greater risk for development of subsequent cancer following ionizing radiation exposure than are adults due to the presence of more radiosensitive developing tissues and to the longer period of time that a radiation-induced cancer has to manifest. It should be stressed that the current knowledge on the risks associated with whole-body radiation doses below 100 mSv is extremely limited. The estimates presented here are based on this limited knowledge and theory and should not be construed as exact estimates. With this in mind, this effort intends to demonstrate that even with conservative estimates, the risk of cancer is extremely low and still warrants even lower CT techniques.

Within the pediatric population, patients at greatest

*Corresponding author.
risk are those who undergo CT procedures with the greatest frequency [5]. Chronic illnesses are being successfully managed with advancing medicine [9,10], but may be accompanied by complications and the need for routine surveillance that require diagnostic imaging. Bone marrow transplant (BMT) patients are an excellent example of such a pediatric patient population. The post transplant period in BMT patients is complicated by infection, graft versus host disease, and secondary malignancies, requiring a high frequency of diagnostic CT imaging for rapid, accurate diagnoses.

To the best of our knowledge, there is no study that investigates the cumulative radiation exposure of diagnostic CT in this particular population. This study addresses radiation exposure in BMT patients and provides an estimate of the additional lifetime risk of cancer attributable to diagnostic CT in a small cohort of pediatric patients who have undergone bone marrow transplantation.

Here we aim to determine the frequency of CT procedures in a cohort of bone marrow transplant patients treated here at Seattle Children’s Hospital. We estimate the effective dose from each CT procedure, and then extrapolate and estimate the lifetime attributable risk (LAR) of cancer (both incidence and mortality).

2. METHODS

IRB approval was obtained for this retrospective analysis. A search for pediatric patients who had undergone bone marrow transplantation and who were subsequently imaged by CT between August 1, 2007 to October 31, 2008 was performed using a radiology information system. CT imaging parameters were collected for all diagnostic CT studies performed on any single patient within this time frame was 3.2 per 15 months. The average Effective Dose (ED) per study was 5.9 +/- 4.5 mSv. The cumulative ED to each patient was on average 20 +/- 32 mSv with a median of 11 mSv.

The CT protocols are defined based on 11 weight-based categories [20]. In each weight category, the average age based on standard growth charts and the average DLP for chest studies in this category was determined to estimate the effective dose from a chest CT in for each protocol (Table 2). These effective dose estimates are plotted in Figure 1.

3. RESULTS

3.1. Patient Cohort

44 patients with bone marrow transplant were included and ranged in age from 7 months to 20 years (average age, 9 years). Indications for bone marrow transplant included acute leukemia (n = 19), chronic leukemia (n = 2), lymphoma (n = 1), immunodeficiency syndrome (n = 14), myelodysplastic syndrome (n = 2), high-risk solid tumor (n = 1), hemophagocytic lymphohistiocytosis (n = 3), and osteopetrosis (n = 2).

3.2. Diagnostic CT

Indications for diagnostic CT in our patient population are listed in Table 1. The number of CT studies performed on any single patient within this time frame was 1 - 13 procedures, and the average number of CT studies was 3.2 per 15 months. The average Effective Dose (ED) per study was 5.9 +/- 4.5 mSv. The cumulative ED to each patient was on average 20 +/- 32 mSv with a median of 11 mSv.

The CT protocols are defined based on 11 weight-based categories [20]. In each weight category, the average age based on standard growth charts and the average DLP for chest studies in this category was determined to estimate the effective dose from a chest CT in for each protocol (Table 2). These effective dose estimates are plotted in Figure 1.

4. DISCUSSION

In this study, the frequency of diagnostic CT procedures in a cohort of bone marrow transplant patients between
Table 1. Breakdown of the varied indications for diagnostic CT in our patient population.

<table>
<thead>
<tr>
<th>Indications for CT</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>36.4%</td>
</tr>
<tr>
<td>Follow-up Pulmonary Opacity</td>
<td>14.6%</td>
</tr>
<tr>
<td>Respiratory Distress</td>
<td>11.9%</td>
</tr>
<tr>
<td>Follow-up Pulmonary Nodule</td>
<td>8.0%</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>6.7%</td>
</tr>
<tr>
<td>Follow-up GVHD*</td>
<td>4.0%</td>
</tr>
<tr>
<td>Concern for EBV/PTLD**</td>
<td>2.3%</td>
</tr>
<tr>
<td>Intracranial Hemorrhage</td>
<td>2.3%</td>
</tr>
<tr>
<td>Headache</td>
<td>1.3%</td>
</tr>
<tr>
<td>Sinus Disease Follow-up</td>
<td>1.3%</td>
</tr>
<tr>
<td>Other</td>
<td>11.2%</td>
</tr>
</tbody>
</table>

*GVHD—Graft versus host disease; **PTLD—Post transplant lymphoproliferative disease.

In this study, the frequency of diagnostic CT procedures in a cohort of bone marrow transplant patients between the ages of 7 months and 20 years was retrospectively observed, and the average effective dose per patient was calculated. Using data from the BEIR VII study, a gross approximation of the additional risk of cancer attributable to these diagnostic CT studies was calculated. This particular patient group is of interest because of the unusually high rate of complications that may be seen following bone marrow transplantation, requiring diagnostic imaging.

The average total effective dose per diagnostic CT procedure in our study, which included both head and body imaging, was 5.9 +/- 4.5 mSv. It was estimated that in this cohort, the CT imaging performed over a 15-month period on a 64-slice scanner led to an average additional lifetime additional risk of cancer incidence of 34 in 10,000 and a lifetime additional risk of cancer mortality of 17 in 10,000. For perspective, in the absence of ionizing radiation, the background overall risk of a cancer death in the USA over a person’s lifetime is 20% - 25% (~2500 in 10,000). Estimates for LAR for cancer incidence for females for a single chest CT acquisition versus patient age are plotted in Figure 2.

Comparable assessments of dose and risk have been performed on other subsets of the pediatric population. Huang et al. [21] evaluated dose related to multi-detector CT for coronary angiography and reported much higher effective doses in the 5-year-old child compared to what we observed in our patient population. This relatively high dose is expected given the higher dose required for detailing coronary arterial anatomy. The EDs ranged from 11.81 - 16.45 mSv, depending on heart rate. This group also estimated the LAR from coronary MDCT, which was much higher in girls than in boys (0.43% - 0.60% in girls; 0.14% - 0.20% in boys). Feng et al. [1] used phantom data to show that the doses from common pediatric CT examinations using a 64-slice MDCT ranged from 0.7 mSv to 3.5 mSv and the associated lifetime cancer risks were found to be up to 0.16%. These values were similar to the 0.06% estimation of lifetime attribute-

Table 2. Summary of diagnostic chest protocols performed during this study. Protocols are presented for 11 patient weight categories (All protocols used proper bow-tie filters are selected to reduce skin dose. All pitches are at 1.375 and obtained at 64 x 0.625 mm). All dosimetry is approximate based on interpolation of age specific models and acquisition settings. Cancer risk is based on estimates from organ-specific doses. For reference, according to the BEIR VII report, the baseline lifetime attributable risk of cancer incidence is approximately 45.5% for men and 36.9% for women. The presented factors are estimates of additional LAR.

<table>
<thead>
<tr>
<th>COLOR</th>
<th>Kilograms</th>
<th>Average Age (years)</th>
<th>kVp</th>
<th>mA range @ 0.5 sec</th>
<th>Effective CT Dose (mSv) [1,2]</th>
<th>Background Equivalent Radiation Time (years)</th>
<th>Additional LAR of cancer incidence attributable to exposure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PINK</td>
<td>6 - 7.4 kg</td>
<td>4 months</td>
<td>100</td>
<td>50 - 70</td>
<td>4.0</td>
<td>1.3</td>
<td>0.06</td>
</tr>
<tr>
<td>RED</td>
<td>7.5 - 9.4 kg</td>
<td>8 months</td>
<td>100</td>
<td>50 - 90</td>
<td>4.6</td>
<td>1.5</td>
<td>0.06</td>
</tr>
<tr>
<td>PURPLE</td>
<td>9.5 - 11.4 kg</td>
<td>15 months</td>
<td>100</td>
<td>50 - 100</td>
<td>4.3</td>
<td>1.4</td>
<td>0.06</td>
</tr>
<tr>
<td>YELLOW</td>
<td>11.5 - 14.4 kg</td>
<td>2.4 months</td>
<td>100</td>
<td>50 - 100</td>
<td>3.9</td>
<td>1.3</td>
<td>0.05</td>
</tr>
<tr>
<td>WHITE</td>
<td>14.5 - 18.4 kg</td>
<td>3.8 months</td>
<td>100</td>
<td>50 - 110</td>
<td>4.0</td>
<td>1.3</td>
<td>0.05</td>
</tr>
<tr>
<td>BLUE</td>
<td>18.5 - 22.4 kg</td>
<td>5.9 months</td>
<td>100</td>
<td>50 - 110</td>
<td>3.3</td>
<td>1.1</td>
<td>0.03</td>
</tr>
<tr>
<td>ORANGE</td>
<td>22.5 - 31.4 kg</td>
<td>8.5 months</td>
<td>120</td>
<td>70 - 120</td>
<td>4.6</td>
<td>1.5</td>
<td>0.04</td>
</tr>
<tr>
<td>GREEN</td>
<td>31.5 - 40.5 kg</td>
<td>10.1 months</td>
<td>120</td>
<td>70 - 150</td>
<td>5.0</td>
<td>1.7</td>
<td>0.04</td>
</tr>
<tr>
<td>BLACK</td>
<td>40.5 - 55 kg</td>
<td>12.8 months</td>
<td>120</td>
<td>70 - 240</td>
<td>7.2</td>
<td>2.4</td>
<td>0.06</td>
</tr>
<tr>
<td>Sm Adult</td>
<td>55 - 70 kg</td>
<td>15.0 months</td>
<td>120</td>
<td>80 - 300</td>
<td>7.6</td>
<td>2.5</td>
<td>0.05</td>
</tr>
<tr>
<td>Lg Adult</td>
<td>&gt;70 kg</td>
<td>20.0 months</td>
<td>120</td>
<td>80 - 300</td>
<td>5.3</td>
<td>1.8</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Copyright © 2012 SciRes.
Figure 1. Estimated effective dose from a standard chest CT acquisition for each age/weight category.

Figure 2. Estimates of additional lifetime attributable risk of cancer incidence from chest CT exam in females. These are based on extremely conservative estimates presented in BEIR VII phase 2 report and the methodology previously presented [11].

More pertinent reviews have been performed on pediatric cancer populations. Pierobon et al. [23] reported the cumulative effective radiation dose associated with radiographic and radioisotopic procedures for 81 pediatric patients with malignant lymphoma over their course of diagnosis, treatment and follow-up. Follow-up periods of the survivors ranged from 2.4 to 12.3 years, and the median effective dose was 309 mSv for non-Hodgkin lymphoma and 518 mSv for Hodgkin lymphoma. These values are much higher than the values we publish in our patient population, even accounting for the 10-fold longer time of study, accountable in part due to nuclear medicine studies performed. Another published review of pediatric cancer patients estimated the radiation dose attributable to PET-CT over a five-year period [24]. The average cumulative radiation dose per patient was 78.9 mSv. Neither of these groups estimated the additional lifetime attributable risk of cancer to these diagnostic studies.

By providing an estimation of risk secondary to CT exams in pediatric BMT patients, this study can be used to refocus our attention on how to lower the radiation exposure to this patient population without decreasing our diagnostic accuracy. The most effective way to reduce dose is to reduce the number of exams. However, pediatric BMT patients are immunocompromised, and so frequent imaging of this patient population is largely justified. If the number of studies cannot be reduced, we...
could consider alternative modalities, such as ultrasound and magnetic resonance imaging, especially for head and abdominal imaging. Yet, for a large percentage of the studies for pediatric BMT patients, CT will remain the best tool. Thus, future efforts may be best focused on reducing dose per CT exam. At our institution, we are employing noise insertion software, as discussed by Karmazyn et al. [25], to simulate lower doses of chest CT and evaluate diagnostic accuracy for detection of pulmonary nodules. This work will lead to protocols with sufficient diagnostic utility at a minimum of dose. An alternative approach may be the gradual transition to using CT scanners with iterative reconstruction techniques for this patient population. Iterative reconstruction techniques have demonstrated the potential for improving image quality and reducing radiation dose in CT relative to the currently used filtered back projection techniques [26-28].

Our study is limited by the inherent uncertainties of calculating cancer risk from low-dose radiation exposure. As detailed in Linet et al. [29], the relationship between radiation and cancer risk can be skewed by confounding factors that are associated with both exposure and disease, but not part of the causal pathway. Models of radiation exposure and cancer risk are subject to a number of statistical uncertainties, and for accurate assessment of these risks, uncertainties should be taken into account [29,30]. Uncertainties also arise from the method of calculating the effective doses and LAR [1,31]. As with the estimates by Feng et al., we could be underestimating the effective doses, because the radio sensitivity of pediatric organs and tissues are higher compared to adults [1]. Reference factors for specific organ sensitivities of varying ages, however, have yet to be developed for more appropriate estimation and application of effective dose in pediatric individuals [1,19].

Diagnostic CT is important in the assessment and management of ill patients following bone marrow transplant. The risk of ionizing radiation leading to additional development of cancer merits using low as a CT technique as reasonable to achieve a diagnostic study. The evaluation presented here provides the imaging trends of bone marrow transplant pediatric patients at a single academic institution. As CT procedures are increasingly being evaluated for dose reduction while maintaining diagnostic specificity, such an inquiry may be of significant assistance to this population with the goal of decreasing lifetime cancer risk.

REFERENCES


Copyright © 2012 SciRes.